Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary therapeutics. The company operates across three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its approved products include JAKAFI (ruxolitinib) for myelofibrosis, polycythemia vera, and graft-versus-host disease; ICLUSIG (ponatinib) for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI (tafasitamab-cxix) and MINJUVI (tafasitamab) for diffuse large B-cell lymphoma and follicular lymphoma; and NIKTIMVO (axatilimab-csfr) for chronic graft-versus-host disease. Incyte markets JAKAFI in the United States through its own specialty sales force, while Novartis holds exclusive rights to develop and commercialize ruxolitinib outside the United States under the name JAKAVI. The company acquired the European operations of ARIAD Pharmaceuticals in 2016 and holds exclusive global rights to tafasitamab following a purchase agreement with MorphoSys in 2024. Incyte also maintains a collaboration with Syndax Pharmaceuticals for axatilimab and recently completed the acquisition of Vega Therapeutics to expand its hematology portfolio. Clinical programs include JAKAFI XR and INCA033989 for myeloproliferative neoplasms.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage incyte.com
Sector Healthcare IR page investor.incyte.com
Tags
hematology, oncology, inflammation, autoimmunity, dermatology, myelofibrosis, graft-versus-host disease, lymphoma, monoclonal antibodies, kinase inhibitors, JAKAFI, ruxolitinib, ICLUSIG, ponatinib, MONJUVI, tafasitamab-cxix, MINJUVI, tafasitamab, NIKTIMVO, axatilimab-csfr, JAKAVI, JAKAFI XR, INCA033989, VGA039, Vega Therapeutics, ARIAD Pharmaceuticals, MorphoSys, Syndax Pharmaceuticals, Novartis
Press page —

Metrics

Valuation  
Market cap $ 24.781B
Market cap (USD) $ 24.781B
P/E 64.61
PEG 1.16
P/BV 4.39
P/S 4.12
P/OCF 33.26
P/FCF 18.64
Dividend yield —
Turnover / mcap —
Returns  
ROE 29.9%
ROI 61.3%
ROIC 55.8%
Profit margin 25.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 55.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 176
Quality score 38.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 5.141B 4.241B 3.696B 3.395B 2.986B 2.667B 2.159B 1.882B 1.536B 1.106B 753.751M 511.495M 354.947M 297.059M 94.455M 169.878M — — 34.44M 27.643M 7.846M 14.146M 47.092M 101.612M 219.263M 194.167M
Net profit 1.287B 32.615M 597.599M 340.66M 948.581M -295.697M 446.906M 109.493M -313.142M 104.222M 6.531M -48.481M -83.147M -44.32M -186.54M -31.846M -211.87M -178.92M -86.881M -74.166M -103.043M -164.817M -166.463M -136.885M -183.235M -29.735M
Free cash flow 1.33B 235.174M 449.001M 892.108M 568.482M -311.978M 632.592M 262.744M -204.009M 184.479M 60.533M -1.62M 4.913M -97.669M -165.514M 93.829M 11.971M -141.558M -93.847M -51.935M -103.505M -116.058M -128.07M -70.156M -59.923M -66.854M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 98.77 69.07 62.79 80.32 73.4 86.98 87.32 63.59 94.71 100.27 108.45 73.11 50.63 16.61 15.01 16.56 2.1 3.25 9.47 3.89 — — — — — —
Price performance 12m 0.43 0.1 -0.22 0.09 -0.16 -0 0.37 -0.33 -0.06 -0.08 0.48 0.44 2.05 0.11 -0.09 6.88 -0.35 -0.66 1.44 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — 18.7M 53.8M 61.7M 60.4M 55.6M 52.6M 60.3M 54.9M
Cash and deposits (USD) 652M 900M 1.16B 1.83B 1.51B 2.06B 2.95B 3.21B 1.69B 3.1B
Intangible assets (USD) 270M 237M — — — — — — — —
Cash flow detail
Operating cash flow (USD) 305M -93M 336M 711M -125M 749M 970M 496M 335M 1.41B
Purchases of property, plant and equipment (USD) -120M -111M -73.5M -78.1M -187M -181M -77.8M — — —
Purchases of intangible assets (USD) — — — — — 0.00 0.00 -15M -13.9M -25M
Change in receivables (cash effect) (USD) -23.9M -118M -41.3M -1.21M -173M -134M -28.6M -98.7M -112M -171M
Change in inventories (cash effect) (USD) 4.05M 4.85M 4.04M -6.1M -19.5M -21M -67.5M -170M -128M -58.5M
Change in payables (cash effect) (USD) 43.8M -7.93M 36.2M -20.2M 15.1M 73.3M 105M -168M 88.2M 6.56M
Share buybacks (cash effect) (USD) — — — — — — 0.00 0.00 -2B 0.00
Interest paid (cash effect) (USD) -7.22M -314,000 -268,000 -239,000 -194,000 -396,000 — — — —
Income taxes paid (cash effect) (USD) -927,000 -6.31M -5.42M -33.6M -70.7M -67.7M -136M -378M -373M -212M
Share-based compensation (USD) 96.2M 133M 148M 167M 178M 183M 188M 216M 266M 249M
Operating cash flow before change in receivables (USD) 329M 24.6M 378M 712M 48.6M 884M 999M 595M 447M 1.58B
Free cash flow (OCF - PPE - intangibles) (USD) 184M -204M 263M 633M -312M 568M 892M — — —
Income detail
Research and development expense (USD) 582M 1.33B 1.2B 1.15B 2.22B 1.46B 1.59B 1.63B 2.61B 2.05B
↳ 5y CAGR +26.6% +44.5% +35.7% +27.1% +35.8% +20.2% +3.6% +6.3% +17.7% -1.5%
Total comprehensive income (USD) 102M -317M 109M 442M -296M 944M 375M 596M 6.39M 1.33B
Comprehensive income to owners (USD) 102M -317M 109M 442M -296M 944M 375M 596M 6.39M 1.33B
Reported Feb 14, 2017 Feb 15, 2018 Feb 14, 2019 Feb 13, 2020 Feb 9, 2021 Feb 13, 2024 Feb 10, 2025 Feb 10, 2025 Feb 10, 2025 Feb 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Incyte Corporation — Other Events Bull 0 Bear 3 Clinical/regulatory

Incyte Corporation (the “Company”) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in patients with ovarian cancer, which had been expected to begin in the fourth quarter of 2026.

The Company’s determination was based on the prioritization of its clinical development portfolio and was not based on any safety or efficacy findings from the INCB123667 clinical program. The Company does not expect this determination to affect its financial guidance or its previously disclosed long-term outlook. 2

November 6, 2026 at 10:40 AM EST

PDF Version

  • University of Maryland School of Medicine will develop an AI-enabled screening platform to support earlier identification and referral of patients with ocular GVHD.

  • H. Lee Moffitt Cancer Center & Research Institute plans to advance understanding of the unique challenges and support needs of caregivers for people living with chronic GVHD.

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte is proud to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute have been selected as the recipients of the 2026 Incyte Ingenuity Awards in GVHD™. This annual award program recognizes and supports innovative projects that address the specific needs of individuals impacted by graft-versus-host disease (GVHD), including patients, caregivers and healthcare providers.

“It is our honor to recognize the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute as recipients of the 2026 Incyte Ingenuity Awards in GVHD,” said Mohamed Issa, Executive Vice President and Head of U.S. Commercial, Incyte. “Their innovative projects address critical needs within the GVHD community, from enabling earlier identification and referral of patients with ocular GVHD to deepening our understanding of the unique challenges faced by caregivers. GVHD can profoundly impact both patients and those who care for them, and these community-driven initiatives have the potential to make a meaningful difference in the lives of those affected.”

The University of Maryland School of Medicine designed its project, Ocular Surface Imaging Guidance and Health Triage (OSIGHT), to improve the early identification of ocular GVHD by developing and evaluating an AI-enabled screening platform for use in transplant clinics. The tool will identify patients at risk and facilitate timely referrals to ophthalmology specialists. By integrating ocular imaging, clinical measurements and patient-reported symptoms, the project seeks to support earlier detection, improve care coordination and preserve vision and quality of life for people living with GVHD.

The H. Lee Moffitt Cancer Center & Research Institute's project, Understanding the Needs of Caregivers Caring for Those with Chronic GVHD, recognizes the important role caregivers play in GVHD care. The initiative seeks to address the lack of research and support resources available to caregivers, an often-overlooked population within the GVHD community. Through in-depth interviews, the initiative will identify GVHD caregivers' unique challenges, stressors and support needs. Insights from the study will be disseminated broadly and help inform the development of future caregiver-focused support programs tailored to improve the well-being of those caring for someone with GVHD.

Applications for the 2026 Incyte Ingenuity Awards in GVHD were evaluated by an independent judging panel consisting of GVHD community experts and advocates, including:

  • Hugo Fernandez, MD, Chair and Medical Director, Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Professor of Oncology, University of South Florida Morsani College of Medicine

  • Christina Ferraro, CNP, Outpatient Advanced Practice Provider Manager, Director of Survivorship, Transplantation and Cellular Therapy and Apheresis, Cleveland Clinic Cancer Institute

  • Kathleen D. Lyons, ScD, OTR/L, Occupational Therapist, Professor of Occupational Therapy, Mass General Brigham University of Health Professions, Director, Cancer Rehabilitation (CaRe) Lab, MGH Institute

  • Lynne Spina, Director of Development and Marketing, BMT InfoNet

To maintain the integrity of the judging process, any judge affiliated with an applying organization was precluded from the review of that organization’s application.

Read more about these winning initiatives and the Incyte Ingenuity Awards in GVHD at https://www.incyteingenuityawards.com/gvhd/.

About GVHD

Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.1

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

1 National Library of Medicine. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. https://www.ncbi.nlm.nih.gov/books/NBK543657/. Accessed May 2026.

Incyte to Present at Upcoming Investor Conferences Bull 0 Bear 0 Routine

November 4, 2026 at 8:00 AM EST

PDF Version

WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 4, 2026-- Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November:

  • Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST)

  • Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT)

  • UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 1:20 pm (GMT)

The presentations will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.

News Release image

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104350871/en/

Incyte Contacts Media [email protected]

Investors [email protected]

Source: Incyte

Investor Relations Inquiries

[email protected]

Incyte

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Cookie Policy

Allow All

Manage Consent Preferences

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details‎

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details‎

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookies Details‎

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details‎

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

Prompts

Incyte Corporation (ticker INCY), listed in United States.

Company History

Date Change Detail
Mar 28, 2003 Renamed INCYTE GENOMICS INC → INCYTE INC
Jul 25, 2000 Renamed INCYTE PHARMACEUTICALS INC → INCYTE GENOMICS INC

ETFs Holding Incyte Corporation

ETF Weight in ETF Shares Market value As of
SAWG 3.28% 792 $ 94.66K Jul 31, 2026
FGSI 2.12% 354 $ 43.284K Nov 11, 2026
SAGP 2.01% 13,606 $ 1.542M Jun 30, 2026
SMRI 1.89% 110,425 $ 13.15M Nov 18, 2026
OASC 1.14% 8,715 $ 1.074M Aug 31, 2026
DSTL 1.04% 195,345 $ 22.144M Jun 30, 2026
LSVD 1.04% 56,481 $ 6.751M Jul 31, 2026
ROE 1.00% 20,777 $ 2.47M Nov 18, 2026
GQQQ 0.76% 10,475 $ 1.25M Nov 18, 2026
CLSE 0.71% 52,015 $ 6.409M Aug 31, 2026
SEIV 0.71% 91,700 $ 10.395M Jun 30, 2026
INFO 0.70% 55,976 $ 6.771M Nov 13, 2026
FEMV 0.66% 310 $ 35.142K Jun 30, 2026
FMDE 0.64% 414,035 $ 46.935M Jun 30, 2026
FTQI 0.61% 49,054 $ 5.9M Nov 16, 2026
AVMV 0.59% 40,439 $ 4.864M Nov 16, 2026
FEMG 0.58% 342 $ 38.769K Jun 30, 2026
FELG 0.58% 286,670 $ 32.497M Jun 30, 2026
AFMC 0.54% 11,750 $ 1.413M Nov 16, 2026
BDVL 0.54% 80,415 $ 9.672M Nov 16, 2026
GQI 0.53% 11,975 $ 1.357M Jun 30, 2026
REGS 0.50% 2,853 $ 323.416K Jun 30, 2026
AFLG 0.49% 37,926 $ 4.561M Nov 16, 2026
BRNY 0.45% 21,132 $ 2.52M Nov 18, 2026
ESLV 0.45% 537 $ 64.182K Jul 31, 2026
VFQY 0.41% 17,137 $ 2.112M Aug 31, 2026
FELC 0.38% 265,695 $ 30.119M Jun 30, 2026
SGLC 0.33% 5,733 $ 706.42K Aug 31, 2026
TMED 0.33% 669 $ 75.838K Jun 30, 2026
BALQ 0.32% 1,138 $ 136.867K Nov 16, 2026
EBI 0.30% 16,889 $ 2.081M Aug 31, 2026
BAMV 0.30% 2,785 $ 343.168K Aug 31, 2026
MKTN 0.27% 2,542 $ 288.161K Jun 30, 2026
AVMC 0.25% 11,399 $ 1.371M Nov 16, 2026
VFMF 0.25% 19,515 $ 2.405M Aug 31, 2026
DFLV 0.20% 128,063 $ 15.585M Nov 12, 2026
FHEQ 0.18% 13,826 $ 1.652M Jul 31, 2026
ESUM 0.16% 2,509 $ 299.876K Jul 31, 2026
AVIE 0.16% 221 $ 26.58K Nov 16, 2026
GVLU 0.16% 3,376 $ 406.032K Nov 17, 2026
ESLG 0.16% 307 $ 36.693K Jul 31, 2026
REMC 0.16% 47 $ 5,327.92 Jun 30, 2026
JSTC 0.15% 3,635 $ 437.181K Nov 17, 2026
FLCV 0.15% 1,659 $ 204.422K Aug 31, 2026
IQSZ 0.14% 2,052 $ 245.255K Jul 31, 2026
FTLS 0.14% 30,875 $ 0.00 Nov 16, 2026
MODL 0.14% 12,339 $ 1.399M Jun 30, 2026
FELV 0.13% 36,585 $ 4.147M Jun 30, 2026
FEAC 0.13% 290 $ 32.874K Jun 30, 2026
DVAL 0.12% 773 $ 87.627K Jun 30, 2026
IALT 0.12% 81,557 $ 9.809M Nov 16, 2026
HBTA 0.12% 2,397 $ 295.358K Aug 31, 2026
DFUV 0.12% 149,966 $ 18.251M Nov 12, 2026
VFVA 0.11% 8,700 $ 1.072M Aug 31, 2026
AVSU 0.11% 4,583 $ 551.197K Nov 16, 2026
DFSU 0.11% 21,476 $ 2.614M Nov 12, 2026
FLSP 0.11% 9,037 $ 1.024M Jun 30, 2026
MSSM 0.11% 6,128 $ 755.092K Aug 31, 2026
GMOV 0.10% 839 $ 103.382K Aug 31, 2026
TACU 0.09% 142 $ 17.078K Nov 17, 2026
DXUV 0.09% 46,183 $ 5.62M Nov 12, 2026
GSPY 0.09% 5,182 $ 623.239K Nov 17, 2026
CAPE 0.09% 1,822 $ 206.542K Jun 30, 2026
VFMO 0.08% 12,933 $ 1.594M Aug 31, 2026
LCTU 0.08% 7,728 $ 929.447K Nov 16, 2026
DFAC 0.08% 554,063 $ 67.429M Nov 12, 2026
DFVX 0.07% 3,164 $ 385.059K Nov 12, 2026
XMAG 0.06% 1,005 $ 122.309K Nov 13, 2026
AVLC 0.06% 7,685 $ 924.275K Nov 16, 2026
BALI 0.06% 7,051 $ 848.024K Nov 16, 2026
DCOR 0.06% 221,299 $ 26.932M Nov 12, 2026
DFAU 0.05% 56,669 $ 6.897M Nov 12, 2026
AVUS 0.04% 51,857 $ 6.237M Nov 16, 2026
DFUS 0.03% 56,374 $ 6.861M Nov 12, 2026
LGDX 0.03% 313 $ 37.645K Nov 17, 2026
NTSD 0.03% 92 $ 10.429K Jun 30, 2026
ACVF 0.03% 345 $ 41.234K Jul 31, 2026
HCMT 0.02% 1,167 $ 139.48K Jul 31, 2026
GDE 0.02% 922 $ 113.609K Aug 31, 2026
NTSX 0.02% 2,577 $ 292.129K Jun 30, 2026
AVLV 0.02% 43,636 $ 5.248M Nov 16, 2026
INRO 0.02% 820 $ 98.621K Nov 16, 2026
AAUS 0.02% 789 $ 90K Nov 18, 2026
MSLC 0.02% 6,165 $ 759.651K Aug 31, 2026
CSHP 0.01% 261 $ 31.39K Nov 16, 2026
DYNF 0.00% 96 $ 11.546K Nov 16, 2026
CORO 0.00% 107 $ 12.913K Nov 16, 2026
NTRL 0.00% 1,896 $ 0.00 Nov 16, 2026